Cooperative Agreement W58P052220006

The Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded a $40.4 million cooperative agreement to Exela Pharma Sciences, LLC (Exela) to expand industrial base capabilities for COVID-19 response. With a period of performance from May 2022 through May 2034, this cooperative agreement will support Exela under the Research on Chemical and Biological Defense program (CFDA 12.360). Through this cooperative agreement, Exela will further the government's...

Nanored LLC received a $246,731 National Science Foundation Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support the development of a novel SARS-CoV-2 virus-like particle optimized to deliver shRNA therapeutics from March 1, 2021 through April 30, 2022. The grant aims to prevent and treat COVID-19 infection through a delivery method utilizing virus-like particles to transport self-amplifying short hairpin RNA molecules into cells. The funding will...

The National Science Foundation (NSF) awarded a $997,689 Cooperative Agreement under its NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to Omnicyte LLC, a minority-owned small business in Branford, CT. The funding supports the design and production of a next-generation COVID-19 vaccine that addresses weaknesses of current vaccines, such as reduced booster effectiveness, short-lived efficacy, and side effects. The project aims to develop a vaccine candidate with improved...

This Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $1,000,000 in funding to the Virginia Biotechnology Research Park Corporation (dba Activation Capital) to develop a robust pharmaceutical cluster program called the Alliance for Building Better Medicine in the Richmond/Petersburg region of Virginia. Over an 18-month period, the awardee will work with 23 core partners, including three direct...

The National Science Foundation Division of Industrial Innovation awarded $255,700 to Creative Biotherapeutics LLC through its Engineering program (CFDA 47.041) on January 15, 2021 to fund the project "SBIR PHASE I: STRESS PATHWAY INHIBITION PREVENTS COVID-19 INFECTION (COVID-19)." This Project Grant will support Creative Biotherapeutics' research efforts through December 31, 2021 to develop inhibitors of stress response pathways to prevent COVID-19 infection. The NSF Engineering...

Superior Nano LLC received a $512,000 National Science Foundation Project Grant to develop dense nanolipid fluid systems for delivering drugs with poor bioavailability. The NSF funding supports research from June 2022 to May 2023 under the Technology, Innovation, and Partnerships program. This award will allow Superior Nano to advance scientific understanding of surfactant-lipid-water systems and create new knowledge applicable to manufacturing drug nanoparticles using twin-screw extrusion. By...

The National Science Foundation Division of Industrial Innovation awarded MBF Therapeutics Inc. a $256,000 Project Grant under the Engineering federal grant program (CFDA 47.041) from January 1, 2022 to December 31, 2022. The grant funds the development of a protective T cell vaccine for SARS CoV-2 (COVID-19). The Engineering program supports innovation, creativity and excellence in engineering research and education to improve quality of life and economic strength. This award furthers those...

This $1,000,000 Cooperative Agreement, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), supports the lead optimization of a novel, broad-spectrum antiviral and immunomodulatory agent to combat coronaviruses, including SARS-CoV-2. The project, conducted by Akanocure Pharmaceuticals Inc., aims to develop an orally administered drug candidate that can suppress viral replication and restore immune system homeostasis,...

This Project Grant from the National Science Foundation's Division of Chemical, Bioengineering, Environmental, and Transport Systems provides $500,000 to the Regents of the University of California at Riverside for research on rapid biomanufacturing of mRNA vaccines in plant chloroplasts. The award period is from January 1, 2022 to December 31, 2023. The research is funded under the NSF Directorate for Engineering's 47.041 CFDA program, which aims to improve quality of life and economic strength...

This $1 million cooperative agreement from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a microbial discovery and biosynthesis platform for targeted protease inhibitors to treat COVID-19. Think Bioscience, Inc. will expand its demonstrated approach using microbial systems to guide the discovery and assembly of protease inhibitors. The company will generate new intellectual property covering the discovery platform and promising small molecules...